Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.

British journal of haematology·2026
Same author

Left and right-side echocardiographic measurement of pulmonary artery stiffness in thoroughbred racehorses.

Journal of equine veterinary science·2026
Same author

A retrospective analysis of phase I and phase I/II investigator-initiated clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK).

ESMO open·2025
Same author

Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.

Blood·2023
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

13.0K

Genetic lesions in diffuse large B-cell lymphomas.

M Testoni1, E Zucca2, K H Young3

  • 1Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 22, 2015
PubMed
Summary
This summary is machine-generated.

Diffuse large B-cell lymphoma (DLBCL), a common adult cancer, is often treated with R-CHOP therapy. This review explores genetic lesions in DLBCL, highlighting its diverse nature and potential for tailored treatments.

Keywords:
BCL2BCl6MYCMYD88NF-κB

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.4K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K

Related Experiment Videos

Last Updated: Apr 18, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

13.0K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.4K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most prevalent adult lymphoma, representing 35-40% of all lymphoma cases.
  • Current standard treatment, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), achieves remission in most patients and cures over half.
  • Significant heterogeneity in clinical presentation, pathology, and biology suggests DLBCL is not a single entity but comprises multiple distinct diseases.

Purpose of the Study:

  • To review the current literature on genetic lesions identified in DLBCL.
  • To underscore the importance of understanding DLBCL heterogeneity for developing targeted therapeutic strategies.

Main Methods:

  • Comprehensive literature search of studies focusing on genetic alterations in DLBCL.
  • Synthesis of findings related to genetic lesions and their potential impact on DLBCL subtypes and treatment response.

Main Results:

  • DLBCL exhibits a wide spectrum of genetic abnormalities.
  • Specific genetic lesions are associated with distinct DLBCL subtypes and may influence treatment outcomes.
  • Understanding these genetic drivers is crucial for advancing DLBCL classification and therapy.

Conclusions:

  • The genetic landscape of DLBCL is complex and diverse.
  • Identifying specific genetic lesions is key to stratifying patients and developing personalized treatment approaches for DLBCL.
  • Further research into DLBCL genetics will likely lead to more effective and targeted therapies.